Testing runs through 42 laboratories and, since 2018, has covered more than 1,400 clinical trials, with over 300 studies active at any one time and around 30 publications a year. Histopathology reaches past routine staining into digital imaging and analysis, multiplex and hybridization imaging, and spatial omics, and the genomics groups add next-generation sequencing and immune repertoire sequencing. Pre-analytical processing and PBMC isolation, protocol development, biospecimen supply, cold-chain logistics, and scientific oversight all sit inside the same centralized lab management structure. Studies also run in cell and gene therapy, inflammation and immunology, metabolics, neurology, rare disease, solid tumors, and hematological malignancies, and testing is offered to medical device and in vitro diagnostic developers. Member laboratories hold CAP accreditation, ISO 15189, GCLP, GLP, CLIA permits, ISO 13485, and ISO 9001, across sites in the Netherlands, Belgium, Canada, South Africa, China, and the United States.
Cerba Research
Cerba Research is a leading global clinical trial laboratory services partner, integrating central lab services, esoteric biomarker testing, and diagnostic assay development. Operating across a vast international network, Cerba Research supports pharmaceutical and biotech sponsors in precision medicine, oncology, and infectious disease clinical trials with robust, regulatory-compliant data.
